anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to neurology, and can be used in treating the patients with chronic ischemic cerebrovascular diseases. That is ensured by a course of hirudotherapy of 10–12 leech fixation procedures. In addition, one procedure of fixing 2–6 leeches on projections of liver, spleen and paraanal and one additional procedure of fixing 4–5 leeches on zone around navel is carried out. Each procedure of fixing leeches is accompanied with a session of Ericsson hypnosis. At the first session, the doctor establishes rapport with the patient, performs semantic analysis of speech, search for key words, assessment of representative systems. Starting from the second procedure of fixing leeches, each session of hypnosis is planned in advance taking into account features of the patient&#39;s personality. At the end of each session, the patient is offered a homework in the form of post-hypnotic suggestion – to draw an image, which came during the session, to conduct a session of self-hypnosis.EFFECT: method provides achieving stable remission in the given group of patients with prolonged remission, especially in patients with non-severe forms of depression, due to reduced risk of thrombosis with simultaneous reduction of depression and anxiety level, manifestation of pain and vestibular syndromes and dissomnic disorders.1 cl, 2 ex, 1 tbl
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a health food product to readily keep a healthy state by positively introducing unnecessary cells into physiological apoptoses.  &lt;P&gt;SOLUTION: This health food product comprises garcinone E, mangostinone or 1,7-dihydroxy-2-isoprenyl-3-methoxyxanthone as an active ingredient. Further, the health food product comprises α-mangostin, β-mangostin or γ-mangostin as an active ingredient and ≤100 mg, preferably 1-50 mg of the active ingredient is orally taken per adult daily. The active ingredients are extracted from the pericarp of Garcinia mangostana Linn. Preferably, the health food product is administered dividedly several times daily. In this case, the intake of the active ingredient for one time is preferably 1-5 mg, more preferably 2-4mg and the α-mangostin has the highest effect as the active ingredient.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain the subject compound useful as e.g. an antitumor agent by clathration of a fluoroprogesterone derivative with a cyclodextrin so as to improve absorbability of the above antineoplastic derivative by oral administration. SOLUTION: This clathrate compound is obtained by reaction of a mixture of a fluoroprogesterone derivative of the formula (R&lt;1&gt; is a 1-23C hydrocarbon group)(e.g. 9α-fluoro-6αmethylprogesterone), cyclodextrin (e.g. dimethylβ- cyclodextrin) and water under agitation for 24 h using a stirrer at room temperature followed by centrifugal separation to remove insolubles and then lyophilizing the resultant supernatant. Next, this clathrate compound is incorporated with cornstarch as vehicle, croscarmellose sodium as disintegrant, sodium laurel sulfate as disintegrating auxiliary and 5% aqueous solution of hydroxypropyl ctellulose to conduct granulation followed by drying and then addition of magnesium stearate as lubricant, thus obtaining art antitumor agent.
METHODS OF THERAPY COMPRISING SIMULTANEOUS ADMINISTRATION OF METHOTREXATE AND FOLIC ACID 5 Methotrexate (MTX) is an antineoplastic agent used the treatment of a wide variety of diseases including cancers and inflammatory autoimmune diseases such as psoriasis, Crohn&#39;s disease, and rheumatoid arthritis. Administered orally or by subcutaneous injection in low doses, MTX inhibits a number of folate dependent metabolic steps that lead to a state of effective folate 0 deficiency. It is likely that some of the adverse effects of MTX are due said folate deficiency, and the main factor affecting adherence to MTX is the occurrence of adverse effects, rather than lack of response. Although MTX side effects could be decreased by supplementation in folic acid (FA), the current guideline on folate administration is not precisely established. Now the inventors show that co-administration of MTX with FA on the same day is effective 5 compared to FA application one day after MTX. MTX metabolism was not affected, as demonstrated by the MTX-PG concentrations. The biological tolerance between the protocols was comparable. Thus, co-administration of MTX and FA seems to be possible and may be more convenient to the patients and improve compliance at the end.
A glucose level control system may be configured to determine a recommended medicament dose based at least in part on a subject&#39;s therapy data and/or user-specified medicament related inputs. The therapy data may include glucose level data and medicament delivery data. The user-specified medicament related inputs may include qualitative meal announcements. For example, the user can specify that the subject consumed a small, medium, or large meal. The glucose level control system may be configured to output an indication of the recommended medicament dose to a display. The glucose level control system may be configured to output a dose control signal to preconfigure a smart pen to deliver the recommended medicament dose. The glucose level control system may be configured to generate an alert if it determines, based at least in part on glucose level data and/or medicament delivery data associated with the subject, that trigger criteria have been satisfied.
PURPOSE:To provide a sebum-suppressing agent exhibiting mild effect and obtained by compounding TOSHISHI and/or its extract as an active component. CONSTITUTION:A remedy for dermatopathy exhibiting mild effect against seborrheic diseases such as acne caused by the excessive secretion of sebum is produced by using TOSHISHI (seed of Cuscuta japonica used singly or as a component of Chinese drug or crude drug preparation having tonic and restorative actions) powder or an extract of TOSHISHI powder produced by extracting with water or aqueous alcohol (e.g. ethanol) at 15-25 deg.C. The amount of the powder or extract is &gt;=0.005wt% in the whole composition and up to 10% in total as dry residue. It can be used in any form applicable to the skin, e.g. cream, ointment, lotion, etc. The agent can be easily permeated into the skin and is absolutely free from irritation. The activity of the agent has no influence on organs other than sebum.
To provide a technology for managing pathological conditions with an ophthalmic examination apparatus installed in the patient&#39;s home. A patient management system of an embodiment includes a server, a plurality of ophthalmic examination apparatuses assigned to a plurality of patients, and a plurality of computers installed in a plurality of medical institutions. The ophthalmic examination apparatuses and computers are communicable with the server via a communication line. The server manages the account of each patient, and the account of each medical institution. Test data obtained by each of the ophthalmic examination apparatuses is stored in the account of a corresponding patient. The server sends information stored in the account of a patient to a computer installed in one of the medical institutions assigned in advance to the patient.
The present disclosure describes an herbal dietary supplement for increasing the testosterone level, libido, and sexual performance of a human. The herbal dietary supplement also increases the energy level of a human. The herbal dietary supplement may be prepared and provided in the forms of a liquid beverage or food bar for oral consumption. In such forms, the herbal dietary supplement comprises Ashwagandha and  Mucuna Pruriens . Other ingredients may be included to further increase a human&#39;s testosterone level, libido, and/or energy level or to customize and/or enhance the effects of the other ingredients in the herbal dietary supplement. Such other ingredients may include, without limitation, Maca,  Tinospora Cordiofolia, Asparagus Racemosus, Orchis Latifolia, Tribulus Terrestris, Anacylus Pyrethrum,  L-dopa,  Epimedium , King Oyster mushrooms, Vitamin-B6,  Ginseng , and D-aspartic acid.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a medicine containing at least one double-stranded oligoribonucleotide (dsRNA) designed to inhibit the expression of a target gene.  &lt;P&gt;SOLUTION: One strand of the dsRNA is at least in part complementary to the target gene. The target gene can be selected from the following group: a cancer gene, a cytokine gene, an Id protein gene, a developmental gene, and a prion gene. The target gene can be expressed in a pathogenic organism (especially, Plasmodium). The target gene can also preferably be a part of a virus or viroid which is pathogenic to human.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new analgesic preparation having remarkably increased analgesic effect.  &lt;P&gt;SOLUTION: The analgesic preparation contains (A) an analgesic agent composed of a propionic acid derivative and (B) one or more compounds selected from glucosamine, its derivative and their salts. Preferably, the analgesic preparation is composed of (A) 1 pt.wt. of an analgesic agent composed of a propionic acid derivative and (B) 0.1-3.3 pts.wt. of one or more compounds selected from glucosamine, its derivative and their salts. More preferably, the analgesic preparation contains one or more compounds selected from glucosamine, its derivative and their salts in an amount of 1-50 mg/kg body-weight/day.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
A vinca alkaloid compound that is substituted at the 20&#39;-position with a carboxamido group is disclosed. The carbonyl of the carboxamido group is bonded to a 20&#39; amino group and to a ring system that contains up to three 5-, 6- or 7-membered rings that are fused or otherwise bonded together. Each ring can be carbocyclic or heterocyclic, with a heterocyclic ring containing up to three hetero ring atoms that are the same or different and are selected from nitrogen, oxygen and sulfur. The ring system can include up to four substituent groups, other than hydrogen, that are discussed within. Methods of preparing the compounds are disclosed as are compositions for their use and methods of treatment using a compound. A particularly preferred compound has an activity in specified cancer cell growth inhibition assays that is the same or better than its parental, unsubstituted vinca compound and is not subject to Pgp-mediated efflux.
1,128,311. Molecular compounds of benzamides and aminobenzoates. MERCK &amp; CO. Inc. 3 Jan., 1966 [11 Jan., 1965], No. 89/66. Heading C2C. [Also in Division A5] The invention relates to molecular compounds formed by combining 3,5-dinitrobenzamide or 2 - methyl - 3,5 - dinitrobenzamide with an equimolecular proportion of an aminobenzoic methyl ester of the formula in which R 2  denotes an alkyl, alkoxy or alkylthio group of 1-5 carbon atoms or a halogen atom and R 3  and R 4  each denote hydrogen or an alkyl group of 1-5 carbon atoms. The compounds are formed by bringing the components together in a solvent or by fusing a mixture of the components. In the solution method an excess of the aminobenzoic ester component may be used. Examples are given of the preparation of compounds from 3,5-dinitrobenzamide (or 2-methyl-3,5-dinitrobenzamide) and methyl 2-ethoxy-4-aminobenzoate. Other products of the invention are listed. The products are useful as additions to poultry feeds (see Division A5).
Preparation of a composition (A) for preventing or curing diseases caused by a microorganism (B) that has, on the outer surface of the cell wall, motifs that interact, in a ligand-receptor fashion, with the mannose receptors of macrophages (MMR). The preparation uses at least one agonist ligand (I) for the nuclear receptor PPARgamma (peroxisome proliferator receptor gamma ). Independent claims are also included for the following: (1) method for extracorporeal treatment of a medium containing macrophages by adding (I) so as to induce and/or amplify expression of MMR; and (2) method for extracorporeal inhibition of proliferation of (B) by adding (I) to a medium infected by (B). ACTIVITY : Antibacterial; Fungicide; Protozoacide; Virucide; Anti-HIV; Immunostimulant. MECHANISM OF ACTION : Macrophage Stimulant. Immunodeficient mice (RAG-2) were treated daily (days 1-6) with 0.01 Micromole of 15d-PGJ2 by intraperitoneal injection and on day 2 infected with 10 7&gt;colony-forming units of Candida albicansby oral gavage. Macrophages were recovered by washing the peritoneal cavity, cultured and tested for phagocytosis of C. albicansby measuring incorporation of tritiated uracil into fungal RNA. The mean index of phagocytosis was 76.32%; compared to 59.82% for animals not treated with 15d-PGJ2.
The invention comprises compounds of the general formula &lt;FORM:0860330/IV (b)/1&gt; and their addition salts (wherein X is a hydrogen or halogen atom or a lower alkyl, halogen (lower) alkyl, lower alkoxy, lower acyl, lower alkanesulphonyl, di-(lower) alkylsulphamoyl or cyano group; A is a divalent, straight or branched C2-6 saturated, aliphatic hydrocarbon group with at least 2 carbon atoms separating the nitrogen atom of the phenthiazine nucleus and the &lt;FORM:0860330/IV (b)/2&gt; group; and R1 and R2 are either lower alkyl groups or together with the adjacent nitrogen atom form a saturated, mononuclear heterocyclic group); and the preparation thereof by oxidizing a compound of the general formula &lt;FORM:0860330/IV (b)/3&gt; is a non-acid medium with not more than a substantially equimolecular proportion of an oxidizing agent that is neither acid itself nor liberates an acid under the reaction conditions used.  A &#34;non-acid&#34; medium is a solvent or emulsifying medium that neither contains an acidic substance nor is capable of liberating such a substance under the reaction conditions used. The qualification &#34;lower&#34; means that the group in question has 1-6 carbon atoms and preferably 1-4 carbon atoms.  Specification 793,227 is referred to.ALSO:A pharmaceutical composition comprises one or more compounds of the general formula &lt;FORM:0860330/VI/1&gt; and their acid addition salts (wherein X is a hydrogen or halogen atom or a lower alkyl, halogen (lower) alkyl, lower alkoxy, lower acyl, lower alkanesulphonyl, di-(lower) alkylsulphamoyl or cyano group; A is a divalent, straight or branched C2-6 saturated, aliphatic hydrocarbon group with at least 2 carbon atoms separating the nitrogen atom of the phenthiazine nucleus and the &lt;FORM:0860330/VI/2&gt; group; and R1 and R2 are either lower alkyl groups or together with the adjacent nitrogen atom form a saturated, mononuclear heterocyclic group) in association with a significant amount of a pharmaceutical carrier. They may be administered orally or parenterally as sedatives, tranquillizers, potentiators of an sthetics (e.g. hexobarbitone and ether) and analgesics, antiemetics, antihistaminics and antiParkinsonian agents; and may take the form of solids or liquids or any combination thereof. The qualification &#34;lower&#34; means that the group in question has 1-6 carbon atoms and preferably 1-4 carbon atoms.  Specified salts are hydrohalides, phosphates, nitrates, sulphates, maleates, fumarates, citrates, tartrates, methanesulphonates and ethanedisulphonates.  Specification 793,227 is referred to.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a cosmetic having a hiding power and effects for enabling the appearance of the texture of the skin to be seen beautifully.  &lt;P&gt;SOLUTION: The cosmetic contains (1) a fiber having a modified cross section having a # shape, and (2) a titanium oxide complex powder. Preferably, the length of the fiber having the modified cross section is 100-1,000 μm, and the fiber has a hollow structure. The fiber is preferably colored red and is preferably a nylon fiber. The titanium oxide complex powder is preferably a complex of titanium oxide with one or more kinds selected from zinc oxide, anhydrous silicic acid, aluminum oxide and zirconium oxide.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for mass-culturing/producing any of various pathogenic microbes as a raw material for vaccines for infectious animal diseases or antigens for infection diagnoses in an efficient step by using a suspendible cultured cell line capable of continuous suspension culture which is created from a normal adhesive monolayer cultured cell line sensitive to various pathogenic microbes including pathogenic virus.  &lt;P&gt;SOLUTION: The suspendible cultured cell line is a canine kidney-derived one which is created from a canine kidney-derived adhesive monolayer cultured cell line. The canine kidney-derived suspendible cultured cell line is either a cell line deposited as an accession No. of FERM P-18443 or a cell line having biological properties equivalent to those thereof. Suspension culture of the cell line enables the efficient mass production of the aimed pathogenic microbes.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
FIELD: medicine, neurosurgery. SUBSTANCE: for dura mater&#39;s transplant one should use analogous brephotissue its size being greater than cranial defect. One should carry out drilling in a bone at the edge of cranial defect. Dura mater&#39;s transplant center by ligatures made of prolongly resolving material through channels perforated in plate&#39;s center. Osseous defect should be closed with a plate to be fixed with ligatures to bones through channels perforated in them. Moreover, cranial defect in wound is applied with sterile transparent and flexible film to apply marks of cranial defect contours onto it together with openings of perforated channels in bones and plate. Then dura mater&#39;s transplant together with adjacent film is cut beyond the contour and film marks. Then one should direct ligatures through film marks of openings and, simultaneously, through transplant, film is removed, and transplant should be fixed by ligatures through osseous channels to internal cranial surface. The method enables to increase efficiency of therapy due to more accurate cutting of dura mater by taking into consideration defect&#39;s shape and disposition of channels perforated in bones and, also, accuracy in directing fixation ligatures. EFFECT: higher efficiency of substitution. 1 cl
Various types of synbiotic therapies are provided for the treatment of a variety of gastrointestinal and other disorders. The combination of prebiotics to probiotics is defined as a synbiotic therapy. The principal GI disorders associated with dysbiosis that can be treated from such a therapeutic intervention include but are not limited to: inflammatory bowel disease (IBD) (Crohn&#39;s disease and ulcerative colitis), irritable bowel syndrome (IBS), antibiotic-associated diarrheas such as recurrent  Clostridium difficile  infection, and possibly variants of Celiac disease. Other disorders that may also be ameliorated by the proposed synbiotic therapy include metabolic syndromes and central nervous system disorders. The disclosed methods and compositions were developed to improve upon currently available probiotics through consideration of the human intestinal microbiota, and its relationship to various intestinal metabolic and neuropsychiatric disorders. In one embodiment, the disclosed synbiotic compositions include prebiotics and a targeted delivery system, which altogether promote the survival, growth, and attachment of probiotic microbiota.
The present invention relates to a medical device with improved biological properties for an at least partial contact with blood, bodily fluids and/or tissues when introduced in a mammalian body, which device comprises a core and a nucleic acid present in a biologically compatible medium. Said nucleic acid encodes a translation or transcription product, which is capable of promoting endothelialisation at least partially on a synthetic surface of said core. The present invention also relates to a method of producing a medical device according to the invention. Further, the present invention also relates to a method of improving a mammalian, preferably human, body&#39;s biocompatibility with a synthetic surface, which method comprises introducing a device according to the invention in the body with an at least partial contact with blood, bodily fluids and/or tissues and administering a nucleic acid present in a biologically compatible medium to the surroundings thereof. Said nucleic acid encodes a translation or transcription product capable of promoting endothelialisation &lt;i&gt;in vivo&lt;/i&gt; at least partially on said synthetic surface. The administration of nucleic acid may in alternative embodiments be performed before, simultaneously as or after the introduction of the device in a body. In addition, combinations of these embodiments are also encompassed.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide compounds and methods enhancing the amount of an agent delivered to a cell or a group of cells.  &lt;P&gt;SOLUTION: Methods and compositions for enhancing transfer of the agent into the cell are provided. The agent may include a polypeptide, a polynucleotide such as genes and antisense nucleic acid, and other molecules. In some embodiments, the agents are modulating agents able to modulate cellular activity or function when introduced into the cell. The methods and compositions are useful for introducing agents into individual cells and cells existing as a tissue or organ.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PURPOSE: To prepare a wound coating material which is designed to make treatment of the skin damaged by burns, wounds, etc., has the excellent transparency, bioaffinity, softness, water permeability, oxygen permeability, etc., of a sheet and has an excellent property to maintain an antimicrobial property over a long period of time. CONSTITUTION: This wound coating material consists of a polyvinyl alcohol sheet contg, &gt;=5% silver-base antimicrobial agent having visible ray transmittance at 380 to 780nm. Such wound coating material is produced by a method of freeze-drying an aq. polyvinyl alcohol soln. contg. the silver-base antimicrobial agent.
NEW MATERIAL:A triazine derivative of formula I (R&lt;1&gt; and R&lt;2&gt; are indentical or different and represent H, hydroxy, halogen, alkoxy including 1-4C alkyloxy and aralkyloxy; X, Y are H, nicotinoyl). EXAMPLE:2-Amino-4-nicotinoylamino-6-beta-naphthyl-S-triazine. USE:It has an action to inhibit edema and is used as an anti-inflammatory agent. Since it inhibits reverse operable Arthus&#39;s reaction, it is used as an antiallergic agent. Further, it has an action to inhibit the coagulation of blood platelets, thus being used as an antithrombotic agent. PREPARATION:The reaction of a known or novel naphthonitrile or naphthoic acid ester of formula II (R&lt;3&gt; is -CN, -COOR&lt;5&gt;; R&lt;5&gt; is lower alkyl) with cyanogunidine or biguanide gives a compound of formula I where X and Y are Hx. Further, an activated derivative of nicotinic acid is made to react therewith to give a compound with nicotinoyl substituents.
The present invention is generally directed to chemically synthesized peptides that are charged with zinc ions (herein “zinc-charged peptides”). The chemically synthesized peptides are based on the amino acid sequence of alpha-lactalbumin. The present invention is further directed to a method of preparing these two zinc-charged peptides by charging the chemically synthesized peptides with zinc ions. It is observed that charging these peptides with zinc ions activate the peptide&#39;s ability to induce apoptosis in cancer cell lines, as well as increase ATP, reduce Tau protein and inhibit P38 in the brain. The zinc-charged peptides are thus capable of treating cancer and diseases involving tauopathy such as Alzheimer&#39;s Disease. The present invention is thus further directed to a method of treating cancer and diseases involving tauopathy such as Alzheimer&#39;s Disease using the zinc-charged peptides.